Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 17;7(2):56-63.
doi: 10.31547/bct-2024-004. eCollection 2024 May 25.

Fostering next generation transplant physicians

Shinichiro Okamoto  1 , Miguel-Angel Perales  2   3 , Anna Sureda  4 , Amado Karduss Urueta  5
Affiliations

Fostering next generation transplant physicians

Shinichiro Okamoto et al. Blood Cell Ther. .

Abstract

As opposed to the rapid expansion of hematopoietic cell transplantation (HCT) and other cellular therapies (CT), we are now facing a global shortage of transplant physicians and other professionals to support the activity of HCT/CT. To overcome this obstacle, a variety of approaches are now being undertaken in four international HCT societies. This article aims to share their current attempts to foster the next generation of transplant physicians and allied professionals needed to secure the continued global growth of HCT/CT.

Keywords: HCT; multidisciplinary team approach; next generation; transplant physician.

PubMed Disclaimer

Conflict of interest statement

MAP reports honoraria from Adicet, Allogene, Allovir, Caribou Biosciences, Celgene, Bristol-Myers Squibb, Equilium, Exevir, ImmPACT Bio, Incyte, Karyopharm, Kite/Gilead, Merck, Miltenyi Biotec, MorphoSys, Nektar Therapeutics, Novartis, Omeros, OrcaBio, Syncopation, VectivBio AG, and Vor Biopharma. He serves on DSMBs for Cidara Therapeutics, Medigene, and Sellas Life Sciences, and the scientific advisory board of NexImmune. He has ownership interests in NexImmune, Omeros, and OrcaBio. He has received institutional research support for clinical trials from Allogene, Incyte, Kite/Gilead, Miltenyi Biotec, Nektar Therapeutics, and Novartis. SO, AS, and AKU declare no conflicts of interest. Disclosure forms provided by the authors are available on the website. SO is a member of the Editor of Blood Cell Therapy. He was not involved in the editorial evaluation or the decision to accept this article for publication.

Similar articles

See all similar articles

References

    1. Ueno NT, Ito TD, Grigsby RK, Black MV, Apted J. ABC conceptual model of effective multidisciplinary cancer care. Nat Rev Clin Oncol. 2010; 7: 544-7. - PubMed
    1. Jenq RR, van den Brink MR. Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer. Nat Rev Cancer. 2010; 10: 213-21. - PubMed
    1. June CH, Sadelain M. Chimeric Antigen Receptor Therapy. N Engl J Med. 2018; 379: 64-73. - PMC - PubMed
    1. Phelan R, Chen M, Bupp C, Bolon YT, Broglie L, Brunner-Grady J, et al. Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes. Transplant Cell Ther. 2022; 28: 409.e1-10. - PMC - PubMed
    1. Auletta JJ, Kou J, Chen M, Bolon YT, Broglie L, Bupp C, et al. Real-World Data Showing Trends and Outcomes by Race and Ethnicity in Allogeneic Hematopoietic Cell Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. Transplant Cell Ther. 2023; 29: 346.e1-10. - PMC - PubMed

LinkOut - more resources